More NewsRead More
Retrophin Receives FDA Orphan Drug Designation for RE-024 for the Treatment of Pantothenate Kinase-Associated Neurodegeneration
May 05, 2015
Retrophin Announces FDA Review of IND for RE-024 and Clearance to Proceed With Phase 1 Clinical Study in Healthy Adult Volunteers
April 30, 2015
Retrophin to Report First Quarter 2015 Financial Results
April 27, 2015
Stocks Hitting 52-Week Highs
May 27, 2015
Retrophin’s Board of Directors Appoints John W. Kozarich, Ph.D. as Independent Director and Names Jeffrey A. Meckler as Chairman
April 01, 2015
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here